JPH08502745A - Ｈｉｖ感染症治療用の他の非‐ヌクレオシド逆転写酵素阻害剤と組み合せてのｂｈａｐ化合物の使用 - Google Patents

Ｈｉｖ感染症治療用の他の非‐ヌクレオシド逆転写酵素阻害剤と組み合せてのｂｈａｐ化合物の使用

Info

Publication number
JPH08502745A
JPH08502745A JP6511044A JP51104494A JPH08502745A JP H08502745 A JPH08502745 A JP H08502745A JP 6511044 A JP6511044 A JP 6511044A JP 51104494 A JP51104494 A JP 51104494A JP H08502745 A JPH08502745 A JP H08502745A
Authority
JP
Japan
Prior art keywords
hiv
therapeutic agent
methyl
amino
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6511044A
Other languages
English (en)
Japanese (ja)
Inventor
タープリー，ウィリアム・ゲーリー
デューウェク，トマス・ジェローム
バッツ，ドナルド・ハーマン，エム・ディ
Original Assignee
ジ・アップジョン・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジ・アップジョン・カンパニー filed Critical ジ・アップジョン・カンパニー
Publication of JPH08502745A publication Critical patent/JPH08502745A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP6511044A 1992-10-28 1993-09-10 Ｈｉｖ感染症治療用の他の非‐ヌクレオシド逆転写酵素阻害剤と組み合せてのｂｈａｐ化合物の使用 Pending JPH08502745A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96763992A 1992-10-28 1992-10-28
US1711993A 1993-02-12 1993-02-12
US08/017,119 1993-02-12
US07/967,639 1993-02-12
PCT/US1993/008354 WO1994009781A1 (en) 1992-10-28 1993-09-10 Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection

Publications (1)

Publication Number Publication Date
JPH08502745A true JPH08502745A (ja) 1996-03-26

Family

ID=26689480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6511044A Pending JPH08502745A (ja) 1992-10-28 1993-09-10 Ｈｉｖ感染症治療用の他の非‐ヌクレオシド逆転写酵素阻害剤と組み合せてのｂｈａｐ化合物の使用

Country Status (12)

Country Link
EP (1) EP0666744A1 (fi)
JP (1) JPH08502745A (fi)
KR (1) KR950703958A (fi)
AU (1) AU4848293A (fi)
CA (1) CA2145545A1 (fi)
CZ (1) CZ69695A3 (fi)
FI (1) FI952018A (fi)
HU (1) HUT72050A (fi)
MX (1) MX9306031A (fi)
NO (1) NO951608L (fi)
PL (1) PL308551A1 (fi)
WO (1) WO1994009781A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
CA2497827A1 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

Also Published As

Publication number Publication date
NO951608D0 (no) 1995-04-27
WO1994009781A1 (en) 1994-05-11
AU4848293A (en) 1994-05-24
PL308551A1 (en) 1995-08-21
KR950703958A (ko) 1995-11-17
CA2145545A1 (en) 1994-05-11
FI952018A0 (fi) 1995-04-27
FI952018A (fi) 1995-04-27
MX9306031A (es) 1994-04-29
EP0666744A1 (en) 1995-08-16
CZ69695A3 (en) 1995-12-13
NO951608L (no) 1995-06-28
HU9501218D0 (en) 1995-06-28
HUT72050A (en) 1996-03-28

Similar Documents

Publication Publication Date Title
AU2006212761B2 (en) Combination therapy
BR112020019189A2 (pt) produtos de combinação que compreendem inibidor de bcl-2 ou inibidor duplo de bcl-2/bcl-xl e inibidor de btk e usos terapêuticos dos mesmos
CN110114071A (zh) 含有取代的吡啶酮的三环化合物以及使用其的方法
CN102481299B (zh) 包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物
CN107406438A (zh) 溴结构域的抑制剂
CN109641838A (zh) Cxcr4抑制剂及其用途
US20230059381A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
CN106573914A (zh) 作为激酶抑制剂的吡唑基‑脲
CA2720908A1 (fr) Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
JP6983945B2 (ja) 自己免疫性疾患の処置
CN111566099B (zh) 抗菌化合物
BR112020019134A2 (pt) produtos de combinação que compreendem inibidor de bcl-2 e mab anti-cd20, ou inibidor de bcl-2, mab anti-cd20 e bendamustina, ou inibidor de bcl-2 e chop e usos terapêuticos dos mesmos
JP6795518B2 (ja) キナーゼを阻害する組成物及び方法
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
JPH08502745A (ja) Ｈｉｖ感染症治療用の他の非‐ヌクレオシド逆転写酵素阻害剤と組み合せてのｂｈａｐ化合物の使用
NZ543109A (en) Method of improved diuresis in individuals with impaired renal function
WO2010060939A2 (en) Combination of hsp90 and herceptin inhibitors
WO2022033460A1 (zh) Btk抑制剂治疗疾病的用途
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
TWI439269B (zh) ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途
US20230064189A1 (en) 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer
TW200404537A (en) Use of the disorazoles and their derivatives for the treatment of benign and malignant oncoses
TW202315615A (zh) Pi3k抑制劑與btk抑制劑在製備治療淋巴瘤的藥物中的用途
CN1997364A (zh) 显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗